Thomas A. Lagace

5.4k total citations · 3 hit papers
32 papers, 4.4k citations indexed

About

Thomas A. Lagace is a scholar working on Surgery, Molecular Biology and Cell Biology. According to data from OpenAlex, Thomas A. Lagace has authored 32 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 21 papers in Molecular Biology and 7 papers in Cell Biology. Recurrent topics in Thomas A. Lagace's work include Lipoproteins and Cardiovascular Health (16 papers), Cholesterol and Lipid Metabolism (11 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Thomas A. Lagace is often cited by papers focused on Lipoproteins and Cardiovascular Health (16 papers), Cholesterol and Lipid Metabolism (11 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Thomas A. Lagace collaborates with scholars based in Canada, United States and Chile. Thomas A. Lagace's co-authors include Jay D. Horton, Neale D. Ridgway, Markey McNutt, Jonathan C. Cohen, Helen H. Hobbs, Zhenze Zhao, Rita Garuti, Hyock Joo Kwon, Susan G. Lakoski and Meghan McDonald and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Thomas A. Lagace

32 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation

2007 647 citations Dawei Zhang, Thomas A. Lagace et al. Journal of Biological Chemistry profile →
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice

2006 548 citations Thomas A. Lagace, Rita Garuti et al. profile →
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote

2006 500 citations Zhenze Zhao, Thomas A. Lagace et al. The American Journal of Human Genetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas A. Lagace Canada	25	3.1k	1.5k	646	588	517	32	4.4k
Sahng Wook Park South Korea	24	2.5k 0.8×	1.9k 1.3×	1.1k 1.7×	447 0.8×	269 0.5×	53	4.4k
Philippe Costet France	32	3.2k 1.0×	2.1k 1.3×	644 1.0×	465 0.8×	157 0.3×	45	4.5k
Young-Ah Moon South Korea	22	1.5k 0.5×	1.5k 1.0×	669 1.0×	257 0.4×	262 0.5×	42	3.1k
Weijun Jin United States	22	1.1k 0.4×	667 0.4×	455 0.7×	229 0.4×	196 0.4×	36	2.3k
Y K Ho United States	32	4.5k 1.5×	3.8k 2.5×	1.9k 2.9×	1.9k 3.2×	1.0k 2.0×	41	9.1k
S. Calandra Italy	39	3.0k 1.0×	1.5k 1.0×	978 1.5×	211 0.4×	413 0.8×	187	5.2k
Maureen Maguire United States	9	1.7k 0.6×	1.9k 1.2×	479 0.7×	207 0.4×	246 0.5×	9	3.5k
Sai Prasad N. Iyer United States	12	1.6k 0.5×	1.8k 1.2×	371 0.6×	691 1.2×	187 0.4×	20	3.3k
Maxime Denis Canada	22	1.4k 0.5×	931 0.6×	285 0.4×	222 0.4×	165 0.3×	27	2.0k
Patrizia Tarugi Italy	30	1.3k 0.4×	743 0.5×	461 0.7×	111 0.2×	289 0.6×	110	2.9k

Countries citing papers authored by Thomas A. Lagace

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Lagace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Lagace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Lagace more than expected).

Fields of papers citing papers by Thomas A. Lagace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Lagace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Lagace. The network helps show where Thomas A. Lagace may publish in the future.

Co-authorship network of co-authors of Thomas A. Lagace

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Lagace. A scholar is included among the top collaborators of Thomas A. Lagace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Lagace. Thomas A. Lagace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Zhenkun, et al.. (2022). Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding. Frontiers in Physiology. 13. 960272–960272. 8 indexed citations

Nikpay, Majid, et al.. (2021). A Common Polymorphism in the FADS1 Locus Links miR1908 to Low-Density Lipoprotein Cholesterol Through BMP1. Arteriosclerosis Thrombosis and Vascular Biology. 41(8). 2252–2262. 7 indexed citations

Goto, Natalie K., et al.. (2020). A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles. Journal of Biological Chemistry. 295(8). 2285–2298. 11 indexed citations

Lau, Paulina, Sébastien Soubeyrand, Robert A. Hegele, Thomas A. Lagace, & Ruth McPherson. (2020). Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia. Atherosclerosis. 304. 39–43. 3 indexed citations

Rasheed, Adil, Sabrina Robichaud, My-Anh Nguyen, et al.. (2020). Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology. 40(5). 1155–1167. 52 indexed citations

Iacocca, Michael A., Jian Wang, Jacqueline S. Dron, et al.. (2018). Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Canadian Journal of Cardiology. 34(10). 1316–1324. 34 indexed citations

Lagace, Thomas A.. (2014). PCSK9 and LDLR degradation. Current Opinion in Lipidology. 25(5). 387–393. 275 indexed citations

Lagace, Thomas A. & Neale D. Ridgway. (2013). The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1833(11). 2499–2510. 186 indexed citations

Weng, Willy, et al.. (2013). Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation. Journal of Biological Chemistry. 288(12). 8279–8288. 140 indexed citations

10.

McNutt, Markey, et al.. (2009). Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells. Journal of Biological Chemistry. 284(16). 10561–10570. 136 indexed citations

11.

Grefhorst, Aldo, Markey McNutt, Thomas A. Lagace, & Jay D. Horton. (2008). Plasma PCSK9 preferentially reduces liver LDL receptors in mice. Journal of Lipid Research. 49(6). 1303–1311. 159 indexed citations

12.

Zhang, Dawei, Thomas A. Lagace, Rita Garuti, et al.. (2007). Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry. 282(25). 18602–18612. 647 indexed citations breakdown →

13.

McNutt, Markey, Thomas A. Lagace, & Jay D. Horton. (2007). Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells. Journal of Biological Chemistry. 282(29). 20799–20803. 227 indexed citations

14.

Zhao, Zhenze, Thomas A. Lagace, Lisa N. Kinch, et al.. (2006). Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote. The American Journal of Human Genetics. 79(3). 514–523. 500 indexed citations breakdown →

15.

Lagace, Thomas A. & Neale D. Ridgway. (2005). The Rate-limiting Enzyme in Phosphatidylcholine Synthesis Regulates Proliferation of the Nucleoplasmic Reticulum. Molecular Biology of the Cell. 16(3). 1120–1130. 77 indexed citations

16.

Ridgway, Neale D. & Thomas A. Lagace. (2003). Regulation of the CDP-choline pathway by sterol regulatory element binding proteins involves transcriptional and post-transcriptional mechanisms. Biochemical Journal. 372(3). 811–819. 30 indexed citations

17.

Henneberry, Annette L., et al.. (2001). Uncoupling Farnesol-induced Apoptosis from Its Inhibition of Phosphatidylcholine Synthesis. Journal of Biological Chemistry. 276(27). 25254–25261. 47 indexed citations

18.

Henneberry, Annette L., Thomas A. Lagace, Neale D. Ridgway, & Christopher R. McMaster. (2001). Phosphatidylcholine Synthesis Influences the Diacylglycerol Homeostasis Required for Sec14p-dependent Golgi Function and Cell Growth. Molecular Biology of the Cell. 12(3). 511–520. 60 indexed citations

19.

Ridgway, Neale D., Thomas A. Lagace, Harold W. Cook, & David M. Byers. (1998). Differential Effects of Sphingomyelin Hydrolysis and Cholesterol Transport on Oxysterol-binding Protein Phosphorylation and Golgi Localization. Journal of Biological Chemistry. 273(47). 31621–31628. 82 indexed citations

20.

Ridgway, Neale D. & Thomas A. Lagace. (1995). Brefeldin A Renders Chinese Hamster Ovary Cells Insensitive to Transcriptional Suppression by 25-Hydroxycholesterol. Journal of Biological Chemistry. 270(14). 8023–8031. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact